Elevated cytoplasmic expression of HuR was found to be a possible indicator of poor prognosis in breast cancer patients that received paclitaxel- and anthracycline-based neoadjuvant chemotherapy (NACT) [66]. The gene discussed is ELAVL1; the disease is breast cancer.